Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Sandra M Sanabria-Bohorquez

Showing results (1-10 of 8) with videos related to

Pageof 1
Sort By:
Drug Discovery Today. Technologies|July 4, 2014
New imaging paradigms in drug development: the PET imaging approachJan Marik, Sandra M Sanabria Bohorquez, Simon-Peter Williams, et al.
Cancer Imaging : the Official Publication of the International Cancer Imaging Society|August 2, 2015
STatistically Assigned Response Criteria in Solid Tumors (STARCIST)Thomas Bengtsson, Sandra M Sanabria-Bohorquez, Timothy J McCarthy, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|February 22, 2008
Whole-body biodistribution and radiation dosimetry of the human cannabinoid type-1 receptor ligand 18F-MK-9470 in healthy subjectsKoen Van Laere, Michel Koole, Sandra M Sanabria Bohorquez, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 19, 2019
A First-in-Human Phase I Study to Evaluate the ERK1/2 Inhibitor GDC-0994 in Patients with Advanced Solid TumorsAndrea Varga, Jean-Charles Soria, Antoine Hollebecque, et al.
Neurology|August 29, 2023
Randomized Phase II Study of the Safety and Efficacy of Semorinemab in Participants With Mild-to-Moderate Alzheimer Disease: LaurietCecilia Monteiro, Balazs Toth, Flavia Brunstein, et al.
Cancer Discovery|March 24, 2017
Phase I Dose-Escalation Study of Taselisib, an Oral PI3K Inhibitor, in Patients with Advanced Solid TumorsDejan Juric, Ian Krop, Ramesh K Ramanathan, et al.
Brain : a Journal of Neurology|December 14, 2019
Cerebrospinal fluid tau fragment correlates with tau PET: a candidate biomarker for tangle pathologyKaj Blennow, Chun Chen, Claudia Cicognola, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 22, 2015
ImmunoPET with Anti-Mesothelin Antibody in Patients with Pancreatic and Ovarian Cancer before Anti-Mesothelin Antibody-Drug Conjugate TreatmentLaetitia E Lamberts, Catharina W Menke-van der Houven van Oordt, Eva J ter Weele, et al.
Pageof 1

Showing results (1-10 of 8) with videos related to

Sort By:
Pageof 1
Drug Discovery Today. Technologies|July 4, 2014
New imaging paradigms in drug development: the PET imaging approachJan Marik, Sandra M Sanabria Bohorquez, Simon-Peter Williams, et al.
Cancer Imaging : the Official Publication of the International Cancer Imaging Society|August 2, 2015
STatistically Assigned Response Criteria in Solid Tumors (STARCIST)Thomas Bengtsson, Sandra M Sanabria-Bohorquez, Timothy J McCarthy, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|February 22, 2008
Whole-body biodistribution and radiation dosimetry of the human cannabinoid type-1 receptor ligand 18F-MK-9470 in healthy subjectsKoen Van Laere, Michel Koole, Sandra M Sanabria Bohorquez, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 19, 2019
A First-in-Human Phase I Study to Evaluate the ERK1/2 Inhibitor GDC-0994 in Patients with Advanced Solid TumorsAndrea Varga, Jean-Charles Soria, Antoine Hollebecque, et al.
Neurology|August 29, 2023
Randomized Phase II Study of the Safety and Efficacy of Semorinemab in Participants With Mild-to-Moderate Alzheimer Disease: LaurietCecilia Monteiro, Balazs Toth, Flavia Brunstein, et al.
Cancer Discovery|March 24, 2017
Phase I Dose-Escalation Study of Taselisib, an Oral PI3K Inhibitor, in Patients with Advanced Solid TumorsDejan Juric, Ian Krop, Ramesh K Ramanathan, et al.
Brain : a Journal of Neurology|December 14, 2019
Cerebrospinal fluid tau fragment correlates with tau PET: a candidate biomarker for tangle pathologyKaj Blennow, Chun Chen, Claudia Cicognola, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 22, 2015
ImmunoPET with Anti-Mesothelin Antibody in Patients with Pancreatic and Ovarian Cancer before Anti-Mesothelin Antibody-Drug Conjugate TreatmentLaetitia E Lamberts, Catharina W Menke-van der Houven van Oordt, Eva J ter Weele, et al.
Pageof 1